July 11, 2025 a 08:38 am
BSX: Analysts Ratings - Boston Scientific Corporation
The Boston Scientific Corporation shows a stable and promising future according to recent analyst ratings. With its broad range of medical devices, the company's innovative solutions continue to drive interest among investors and analysts. The current analyst ratings suggest strong confidence, with significant "Strong Buy" and "Buy" recommendations dominating the sentiment.
Historical Stock Grades
The latest analyst ratings indicate a strong overall sentiment towards BSX, reflecting in the following table.
| Recommendation | Number | Score |
|---|---|---|
| Strong Buy | 8 | |
| Buy | 24 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the past months, the sentiment towards Boston Scientific Corporation's stock has shown a shift towards more favorable ratings. The continuous strong ratings in the "Buy" category solidify the company's market position.
- The "Strong Buy" ratings have shown a slight decrease over the past months, but remain solid.
- "Buy" ratings have been consistent, indicating sustained confidence in the company's prospects.
- The number of "Hold" ratings has been relatively stable, indicating a neutral view among some analysts.
Percentage Trends
Within the last year, there has been a notable shift in analyst ratings percentage-wise. The following trends summarize the changes:
- There has been a slight decline in "Strong Buy" ratings from the previous year.
- The percentage of "Buy" ratings has remained a dominant force in the sentiment landscape.
- "Hold" ratings have seen minor fluctuations but do not indicate a significant shift in sentiment.
- No recent indicators of a shift towards "Sell" or "Strong Sell" sentiments, demonstrating strong market confidence.
Latest Analyst Recommendations
Recent analysts’ recommendations maintain a steady outlook on the stock. The table below shows insignificant changes in sentiment, preserving ongoing support.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-28 | Buy | Buy | Needham |
| 2025-05-22 | Buy | Buy | Citigroup |
| 2025-05-16 | Overweight | Overweight | Morgan Stanley |
| 2025-04-25 | Overweight | Overweight | Barclays |
| 2025-04-24 | Outperform | Outperform | Baird |
Analyst Recommendations with Change of Opinion
In the cases of changing recommendations, a predominant trend of upgrades can be noticed, suggesting increased confidence as per the latest shifts.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-16 | Buy | Hold | Needham |
| 2024-10-18 | Hold | Buy | Needham |
| 2024-02-01 | Buy | Neutral | Mizuho |
| 2022-05-27 | Buy | Hold | Needham |
| 2022-05-26 | Buy | Hold | Needham |
Interpretation
From the data presented, the market sentiment towards Boston Scientific Corporation's stock remains generally positive. The consistent "Buy" and occasional "Strong Buy" ratings indicate an established faith in the company's performance and future growth. The few downgrades to "Hold" reflect isolated cautious sentiments, but overall confidence remains intact. The lack of "Sell" recommendations highlights a stable market trust in the company's potential.
Conclusion
In conclusion, Boston Scientific Corporation enjoys a positive market sentiment, with strong indications of continued investor confidence. The current positive ratings affirm the company's potential for growth based on its innovative medical device offerings. While there have been isolated instances of downgrades, they have not significantly impacted the bullish outlook. This assessment emphasizes the importance of monitoring market reactions closely to capitalize on opportunities while being wary of potential market volatility in the medical devices segment. Overall, Boston Scientific Corporation appears well-positioned for future success.